Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 10, 2020
Emerging Company Profile
Autobahn: fine-tuning thyroid agonism to remyelinate axons
Arch-incubated remyelination play Autobahn launches with $76M series B
BioCentury | Aug 17, 2018
Targets & Mechanisms
Unsaturated remyelination
Case Western spins out Convelo to develop remyelination drugs
BioCentury | Jun 8, 2017
Translation in Brief
Barrier gateways
BBB cell models open windows into two CNS disorders
BioCentury | Nov 17, 2016
Translation in Brief
Hormones in harness
Glucagon and T3 bring out the best in each other for metabolic diseases
Items per page:
1 - 10 of 15